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Abstract
We examined longitudinal associations of vitamin D receptor (VDR) and megalin (LRP2; LDL receptor-related protein-2) gene polymorphisms with central
adiposity. We used data from the Baltimore Longitudinal Study of Aging (BLSA), an ongoing prospective open cohort study. Study participants consisted of
non-Hispanic white adults residing in Baltimore city, with one or more visits at age≥50 years, and complete data (n 609–617). Repeated assessments on
waist circumference (WC) and waist:hip ratio (WHR) were available. Multiple linear mixed models were used to estimate mid-follow-up age central adiposity
level and annual rate of change with cut-points set at the sex-speciﬁc 80th percentile. The four binary outcomes were: ‘elevated central adiposity’ (ECA-WC
and ECA-WHR) and ‘signiﬁcant increase in central adiposity’ (SICA-WC and SICA-WHR). SNP for VDR (four SNP: (1) rs11568820 (CdX-2:T/C);
(2) rs1544410 (BsmI:G/A); (3) rs7975232 (ApaI:A/C); (4) rs731236 (TaqI:G/A)) and Megalin (three SNP: (1) rs3755166:G/A; (2) rs2075252:C/T;
(3) rs4668123:C/T) genes were selected. SNP latent classes (SNPLC) and SNP haplotypes (SNPHAP) were created. Multiple logistic regression analyses
indicated that, in men, higher ECA-WHR odds were associated with SNPLC Megalin2:rs3755166[–]/rs2075252[TT]/rs4668123[T–]( v. Megalin1:
rs3755166[–]/rs2075252[CC]/rs4668123[–]) (OR 2·87; 95 % CI 1·15, 7·12; P=0·023) and that SNPLC Megalin3:rs3755166[–]/rs2075252[CT]/
rs4668123[–]( v. Megalin1) was linked to lower SICA-WC odds (OR 0·48; 95 % CI 0·26, 0·88; P=0·019) (P>0·05 for sex×SNPLC). In women,
VDR3 SNPHAP (GAA:bAT) was related to lower odds of ECA-WC (OR 0·37; 95 % CI 0·16, 0·87; P=0·023) (P<0·05 for sex×SNPHAP), VDR1
SNPHAP (GCA:baT) was associated with greater odds and VDR3 SNPHAP (GAA:bAT) with lower odds of SICA-WC (P >0·05 for
sex×SNPHAP). Vitamin D-related gene polymorphisms were associated with central adiposity status and change. Future mechanistic studies are needed
to conﬁrm those polymorphisms’ biological signiﬁcance to central adiposity.
Key words: Central adiposity: SNP: Vitamin D receptor: Megalin: Adults
Human adiposity is heritable and polygenic
(1), with genes con-
tributing 16–85 % for BMI
(2) and 37–81 % for waist circum-
ference (WC) (for example, Hunt et al.
(3)). Gene–environment
interactions may largely determine adiposity phenotypes.
Moreover, serum 25-hydroxyvitamin D (25(OH)D) concen-
tration correlated inversely with adiposity and related meta-
bolic disorders
(4). The lower bioavailability of the fat-soluble
vitamin D through its sequestration into excessive fat tissues
was a suggested mechanism
(5), implicating obesity in the aetiol-
ogy of vitamin D deﬁciency. Conversely, vitamin D may play a
causal role in obesity by modulating homeostasis of intracellu-
lar Ca which correlates inversely with dairy product consump-
tion. Ultimately, a higher intracellular Ca triggers lipogenesis
and suppresses lipolysis
(6).
Abbreviations: BLSA, Baltimore Longitudinal Study of Aging; ECA, elevated central adiposity; LCA, latent class analysis; LD, linkage disequilibrium; SICA, signiﬁcant increase
in central adiposity; SNPHAP, SNP halotype; SNPLC, SNP latent class; VDR, vitamin D receptor; WC, waist circumference; WHR, waist:hip ratio.
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1Vitamin D’s active form (1,25-dihydroxyvitmain D3 (1,25
(OH)2D3)) binds directly to the nuclear vitamin D receptor
(VDR). The VDR gene is located on chromosome 12
and contains fourteen exons (chr12q13·1). The VDR–1,25
(OH)2D3 complex modulates transcription of vitamin
D-responsive genes
(7) and inﬂuences adipocyte differentiation
both in vitro and in vivo
(8). Epidemiological studies show associ-
ations of VDR gene polymorphisms with adiposity and related
metabolic disorders
(9–17). However, most studies speciﬁcally
examining adiposity outcomes had small sample sizes (<400)
(for example, Grundberg et al.
(10), Filus et al.
(11) and Speer
et al.
(15)), some were restricted to one sex (for example,
Ochs-Balcom et al.
(9) and Grundberg et al.
(10)) but, more
importantly, all were cross-sectional or case–control by
design
(9–17). Thus, our present study is, to our knowledge,
the ﬁrst one to examine VDR gene polymorphisms in relation
to longitudinal adiposity outcomes.
Another endocytic vitamin D-binding receptor, known as
megalin (or LDL receptor-related protein-2; LRP2), is expressed
in many epithelial cells, belongs to the LDL receptor family and
its expression isdirectly regulated by bothvitamin D and vitamin
A
(18). Vitamin D enters cells via megalin receptor bound to vita-
minD-bindingprotein
(19).Megalininﬂuencesobesitypossiblyby
mediating the transport of the appetite-regulating adipokine lep-
tin through the blood–brain barrier and modulates leptin signal-
ing
(20). Leptin, in turn, was linked to vitamin D metabolism by
attenuating gene expression of renal enzyme 25-hydroxyvitamin
D3-1α-hydroxylase in mice
(21). Megalin also facilitates transcyto-
sis of precursor hormone thyroglobulin
(22). Leptin and thyroid
hormone collectively affect adiposity through their regulation
of energy metabolism, thermogenesis, glucose and lipid metab-
olism, appetite and food intake, and the oxidation of fatty
acids
(23). Megalin is also a receptor for sex hormone-binding
globulin. In fact, a cross-effect modiﬁcation of oestrogen and
vitamin D interventions was observed for colorectal cancer inci-
dence in the Women’s Health Initiative trial
(24), suggesting an
interplay of oestrogen and vitamin D via megalin and a possible
differential effect of megalin polymorphisms between sexes. To
our knowledge, aside from recent genome-wide association
studies (for example, Heid et al.
(25)), no study using a candidate
gene approach has thus far examined megalin gene polymorph-
ism in relation to adiposity phenotypes, particularly longitudinal
changes in central adiposity, though these variations were tested
for outcomes such as cognition and dementia
(26), a phenotype
shown to be associated with obesity in a recent meta-analysis
(27).
In our present study, we hypothesise that selected poly-
morphisms in VDR and megalin genes previously shown to
affect various metabolic and cardiovascular health outcomes,
mainly in cross-sectional studies, are also associated with cen-
tral adiposity status and longitudinal changes in a sample of
non-Hispanic white US adults.
Materials and methods
Database and study subjects
Data from the Baltimore Longitudinal Study of Aging (BLSA)
were used, with methods summarised elsewhere
(28). Eligible
participants for our present study had at least one visit at or
beyond age 50 years (n2 2321 of 3005), and were restricted
further to non-Hispanic whites (n3 1917), given possible differ-
ential associations of vitamin D status with adiposity in
different ethnic groups. Complete genetic data among those
non-Hispanic white participants eligible for analysis were avail-
able for n4 702 BLSA participants, of whom n4 609–617 had
complete central adiposity and covariate measurements. The
present study was conducted according to the guidelines laid
down in the Declaration of Helsinki and all procedures invol-
ving human subjects were approved by the the Institutional
Review Board (IRB) of Medstar Health Research Institute.
Written informed consent was obtained from all subjects. In
addition, genetic and other variables were de-identiﬁed for
the purpose of statistical analysis.
Data collection and key measurements
Classification of elevated central adiposity and significant
increase in central adiposity. BLSA staff clinicians assessed
WC with a tape measure kept parallel to the ﬂoor, from the
hipbone and wrapping around the waist at navel level while
participants were holding their breath. Hip circumference
was similarly measured and waist:hip ratio (WHR) was
computed accordingly. Multiple assessments were available
(WC, n 14 852 visits, n 2886 subjects; WHR, n 14 832
visits, n 2886 subjects) and mean and range of individual
assessments (or visits) were: WC, mean 5·1 (range 1–25);
WHR, mean 5·1 (range 1–25, with more than 90 % of
participants having at least two visits.
We conducted linear mixed models to predict individual WC
and WHR at mean follow-up age and estimate annual rate of
change between age 50 years and mean follow-up age (see
online Supplementary Material S2), an approach previously
used to predict cognitive performance and annual rate of
change
(26). Using sex-speciﬁc quintiles, binary outcomes ‘elev-
ated central adiposity’ (ECA) and ‘signiﬁcant increase in central
adiposity’ (SICA)weredeﬁnedasthe uppermostquintile (value
=1) for central adiposity level and annual rate of change,
respectively, and compared with all other quintiles combined
(value= 0). ECA and SICA were deﬁned for WC and WHR,
and thus four binary outcomes were obtained (ECA-WC,
ECA-WHR, SICA-WC and SICA-WHR). The choice of the
binary outcome (as opposed to a continuous one) was driven
by the potential clinical signiﬁcance of the effects as well as
the ease of interpretation and replication in future studies that
would use similar cut-points in independent samples.
Genotyping strategy and gene polymorphism classification:
SNP, SNP latent classes and SNP haplotypes. DNA,
extracted from collected blood samples, was used for
genome-wide genotyping on 1231 BLSA participants with
Illumina 550K. HapMap-CEU (http://hapmap.ncbi.nlm.nih.
gov/; build 36) was also used to impute approximately 2·5
million SNP with MACH
(29). CEU is a population sample of
Utah residents with Northern and Western European ancestry
from the CEPH (Council on Education for Public Health)
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frequency of <1 % were excluded. SNP were selected from
ﬁndings of conﬁrmatory candidate gene studies of adiposity
or various health outcomes that are linked to adiposity
(9–16,26).
Most VDR SNP were available in our database, with few
exceptions (for example, VDR SNP rs10735810, FokI:G/A).
Consequently, four VDR SNP (rs11568820 (Cdx-2:T/C);
rs1544410 (BsmI:G/A); rs7975232 (ApaI:A/C); rs731236
(TaqI:G/A)) and three megalin SNP (rs3755166:G/A;
rs2075252:C/T; rs4668123:C/T) were chosen (online
Supplementary material S1, Fig. S1(a) and Fig. S1(b)).
Using latent class analysis (LCA) with sex and ﬁrst-visit age
as covariates and selected SNP entered into that model (one
gene per model) as a three-level categorical variable, VDR
and megalin SNP latent classes (SNPLC) were obtained
(PROC LCA in SAS version 9.1; SAS Institute Inc.)
(30).
Akaike information and Bayesian information criteria for
model ﬁt determined the appropriate number of latent classes.
Using the Bayes theorem, posterior probabilities were esti-
mated and were identical for all individuals with a particular
SNP pattern per gene. Each individual belonged to a speciﬁc
SNPLC when the posterior probability for this class was
>0·50. For most individuals, the expected posterior probability
is >0·90 for a speciﬁc latent class
(30) (online Supplementary
material S1, Fig. S1(a) and Fig. S1(b)).
Additionally, using Haploview version 4.2
(31), SNP haplo-
types (SNPHAP) per gene were also created. For the VDR
gene, three SNP (BsmI, ApaI and TaqI) with moderately strong
linkage disequilibrium (LD) were combined into SNPHAP, as
was done in previous studies (for example, Beydoun et al.
(26)).
Consequently, three SNPHAP were prevalent in our popu-
lation, combining BsmI, ApaI and TaqI as follows: VDR1,
GCA (baT), VDR2, AAG (BAt) or VDR3, GAA (bAT) for
one or two alleles. We coded participants as: 0= having no
VDRx haplotype; 1 = having one allele carrying the VDRx
haplotype; 2 =having two alleles carrying the VDRx haplo-
type. Using a similar approach, eight megalin haplotypes
were uncovered. However, only three megalin SNPHAP
were selected for our analysis (prevalence with one or two
copies was >10 %). Both SNPLC and SNPHAP have been
created and used in a similar fashion in a previous study
(26).
Other main covariates. To adjust for potential confounding
in the main associations of interest, three sets of covariates
were considered: (1) sociodemographic factors, namely
ﬁrst-visit age and mean follow-up ages (per individual and
outcome), sex, educational attainment (years of schooling),
and one lifestyle-related factor, namely smoking status
(never, former or current smoker); (2) self-reported history
of type 2 diabetes, hypertension, CVD (stroke, congestive
heart failure, non-fatal myocardial infarction or atrial
ﬁbrillation) and dyslipidaemia at ﬁrst visit. Only covariates
(1) were considered as potential confounders in multiple
regression models, whereas (2) were only used for
descriptive purposes. In addition, EIGENSTRAT analysis
(implemented as part of the EIGENSOFT package) was
conducted and two top principal components were added in
multiple regression models to control for any residual effects
of population structure as described in a previous study
(26).
The EIGENSTRAT method is a program that conducts
principal components analysis to correct for stratiﬁcation in
genome-wide association studies.
Statistical analysis
For each selected SNP, we assessed Hardy–Weinberg equili-
brium with an exact test, using Haploview version 4.2
(31),
and calculated pair-wise LD. Online Supplementary Material
S3 shows the LD map for all available VDR and megalin
SNP. We present means and proportions of study sample
characteristics, gene SNP, SNPLC and SNPHAP distributions.
Further, we conducted multiple logistic regression analyses
to examine associations of VDR and megalin SNP, SNPLC
and SNPHAP with four binary central adiposity: (1)
ECA-WC; (2) ECA-WHR; (3) SICA-WC; (4) SICA-WHR
(see online Supplementary Material S2).
A two-stage Heckman selection model was constructed to
account for selection bias due to non-random participant selec-
tion for genetic analysis, as was done in several other studies
(for example, Beydoun et al.
(26)). At a ﬁrst stage, a probit model
produced an inverse Mills ratio (IMR), directly derived from the
predictedprobabilityofbeingselected,conditionalonmodelcov-
ariates.Toadjustforthisselectionbias,theIMRenteredthemain
multiple logistic regression models as a covariate in the second
stage. Stratiﬁed analyses by sex were conducted. Effect modiﬁ-
cation by sex was tested by adding interaction terms of sex with
SNP, SNPLC and SNPHAP. In particular, sex differences in
theassociationbetweenmegalingenepolymorphismandvarious
phenotypes including adiposity were hypothesised a priori
(24).
With the null hypothesis being no association between SNP
(or SNPHAP, SNPLC) and the four main outcomes of interest
((1) ECA-WC; (2) ECA-WHR; (3) SICA-WC; (4) SICA-WHR),
type I errors were generally set at 0·05, with main effect P values
between 0·05 and 0·10 labelled as marginally signiﬁcant,
whereas a P value below 0·10 was considered signiﬁcant for
interaction terms, as was done in other studies (for example,
Beydoun et al.
(26)) before correction for multiple testing.
Multiple testing correction was done using a familywise
Bonferroni procedure, whereby a family was deﬁned by adi-
posity outcome type (i.e. status (ECA) v. change (SICA))
(32).
Within each outcome, two alternate measures were used,
namely WC and WHR. The corrected statistical signiﬁcance cri-
terion for main effect P values was reduced to P=0·05/2=
0·025 (marginal signiﬁcance: P=0·10/2=0·050). Because of
their lower statistical power compared with main effects, inter-
action terms’ critical P values were reduced to 0·05
(33). All ana-
lyses (except for LCA) were performed using Stata version 11.0
(StataCorp LP)
(34).
Results
Study sample characteristics and gene SNP distribution
Study sample characteristics are summarised in Table 1. All ex-
amined SNP were in Hardy–Weinberg equilibrium (P >0·05).
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(r2>0·5) while Cdx-2 SNP was independent. In fact, BsmIa n d
ApaI both occur in the intron separating exons 8 and 9
(35).I nt h e
megalin gene, rs4668123 and rs2075252 were in moderate LD
(r2 0·42) while rs3755166 was independent (r2<0·20) (online
Supplementary material S1, Fig. S1(a) and Fig. S1(b)). For each
SNP, one genotype had a relative frequency >40 % and thus
was dominant compared with the other genotypes. SNPLC
and SNPHAP distributions are also presented in online
Supplementary material S1, Fig. S1(a) and Fig. S1(b).
Vitamin D receptor and megalin SNP’s associations with
central adiposity
Table 2 examines, among others, the association between
VDR SNP (entered alternatively, models 1·1–2·8) and
central adiposity (ECA-WC, ECA-WHR, SICA-WC and
SICA-WHR), using multiple logistic regression models. Most
associations were non-signiﬁcant, after Bonferroni correction
(refer to type I error correction in Statistical analysis section).
However, having a CC (v. AA) genotype on the ApaI:A/C
SNP increased the risk of SICA-WHR (OR 1·76; 95 % CI
1·06, 2·92; P=0·029) with a clear dose–response relationship
with each A nucleotide (P for trend = 0·024).
Similarly, when megalin SNP were entered simultaneously
into models with each of the four outcomes (models 3·1–4·2),
after correction for multiple testing, we found that the TT geno-
type contrasted with CC for Megalin:rs2075252:C/T was associ-
ated with a signiﬁcantly higher odds of ECA-WHR (OR 2·14;
95 % CI 1·15, 3·99; P=0 ·017) with a marginally signiﬁcant
dose–response relationship (P for trend=0·042).
Vitamin D receptor and Megalin SNP latent classes’
associations with central adiposity
Using LCA, three SNPLC per gene were created. One key
ﬁnding emerged for SNPLC related to central adiposity in
the total population (Fig. 1(a) and Fig. 1(b)). Comparing
each minor SNPLC with the most dominant one, we found
that Megalin2 v. Megalin1 was associated with signiﬁcantly
increased odds of ECA-WHR in the total population (OR
2·34; 95 % CI 1·18, 4·64; P =0 ·015), which remained signiﬁ-
cant after correction for multiple testing (Fig. 1(b)).
Vitamin D receptor and Megalin SNP latent classes’
associations with central adiposity: sex-stratified findings
In Table 3, we conducted similar regression models as in Fig. 1
(a) and Fig. 1(b), but stratifying by sex. Although sex differ-
ences were not statistically signiﬁcant when testing sex×
SNPLC interaction terms in separate models (P >0·05),
some of the signiﬁcant associations that were detected in the
total population were restricted only to men (Megalin2 v.
Megalin1 (ECA-WHR): OR 2·87; 95 % CI 1·15, 7·12; P =
0·023; and Megalin3 v. Megalin1 (SICA-WC): OR 0·48; 95 %
CI 0·26, 0·88; P =0·019) and retained signiﬁcance after cor-
rection for multiple testing. However, none of the VDR
SNPLC associations with central adiposity were signiﬁcant
after this type of correction (P >0·025).
Vitamin D receptor and Megalin SNP halotypes’ associations
with central adiposity
Using haplotype analysis, three SNPHAP per gene were cre-
ated. Each of those six SNPHAP was entered separately in
the main multiple logistic regression models as an ordinal vari-
able. In both sexes combined, VDR1 SNPHAP was associated
with an increased odds of SICA-WHR (OR 1·31; 95 % CI
1·01, 1·69; P=0·038), though signiﬁcance was not retained
after correction for multiple testing (Fig. 2(a) and Fig. 2(b)).
Vitamin D receptor and Megalin SNP halotypes’ associations
with central adiposity: sex-stratified findings
Our sex-stratiﬁed analysis with SNPHAP (Table 4) uncovered
many important ﬁndings, particularly for VDR SNPHAP.
Among those key ﬁndings, VDR3 SNPHAP was associated
Table 1. Study sample characteristics (Baltimore Longitudinal Study
of Aging)
(Number of subjects and percentages, mean values and standard
deviations)
n %
Female 702 47·85
Age at first visit (years) 702
Mean 52·34
SD 16·7
≤20 1 0·14
21–29 62 8·83
30–39 130 18·52
40–49 160 22·79
50–59 113 16·10
60–69 94 13·39
70–79 92 13·11
80 + 50 7·12
Education at first visit (years) 674 –
Mean 16·85
SD 2·53
Smoking status at first visit 644
Never 254 39·44
Former 271 42·08
Current 119 18·48
Type 2 diabetes at first visit 702 1·28
Hypertension at first visit 689 27·00
CVD at first visit* 702 3·85
Dyslipidaemia at first visit 702 6·70
Central adiposity outcomes†
ECA
WC>100·40 cm (men); >88·80 cm (women) 631 22·7
WHR >0·968 (men); >0·846 (women) 631 22·5
SICA
WC>0·448 cm (men); >0·583 (women) 631 30·9
WHR >0·0025 (men); >0·0038 (women) 631 34·2
ECA, elevated central adiposity; WC, waist circumference; WHR, waist:hip ratio;
SICA, significant increase in central adiposity.
* Reported any of the following conditions at first visit: stroke, congestive heart fail-
ure, non-fatal myocardial infarction, or atrial fibrillation.
† WC and WHR were predicted at mean age at follow-up using a multivariate linear
mixed model controlling for sex, race/ethnicity, education (years), and smoking sta-
tus, with age added among the fixed-effect variables to allow for quadratic non-linear
change. The slope or annual rate of change was predicted from these models at the
mean age at follow-up (i.e. between age 50 years and individual mean age of
follow-up for each central adiposity measure) (see online Supplementary Material
S2 for more details).
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%C I0 ·16, 0·87; P =0 ·023) with signiﬁcant sex differences (P
<0·05 for sex× SNPHAP interaction term). This ﬁnding was
replicated for SICA-WC in women (OR 0·40; 95 % CI 0·19,
0·87; P =0 ·020), though without signiﬁcant sex differences.
Moreover, among women only, VDR1 was related to an
increased odds of SICA-WC (OR 1·87; 95 % CI 1·14, 3·07;
P=0·014) without signiﬁcant sex differentials. Those
Table 2. Vitamin D receptor (VDR) and Megalin gene SNP associations with predicted central adiposity outcomes: multiple logistic regression analysis
(Baltimore Longitudinal Study of Aging)
(Odds ratios and 95 % confidence intervals)
Predicted central adiposity outcomes‡
ECA SICA
n OR§ 95 % CI P for trend n OR§ 95 % CI P for trend
VDR SNP: WC: models 1·1–1·8
VDR: rs11568820 (CdX-2:T/C) 617 617
TT=0 1 0·415 1 0·456
CT= 1 0·88 0·29, 2·61 0·81 0·26, 2·49
CC= 2 1·10 0·38, 3·14 1·01 0·34, 2·99
VDR: rs1544410 (BsmI:G/A) 616 616
GG= 0 1 0·346 1 0·694
GA= 1 1·05 0·68, 1·63 0·85 0·55, 1·31
AA =2 1·34 0·77, 2·35 0·94 0·53, 1·66
VDR: rs7975232 (ApAI:A/C) 617 617
AA =0 1 0·670 1 0·064†
AC = 1 0·83 0·53, 1·31 1·26 0·80, 2·00
CC= 2 0·91 0·53, 1·57 1·69† 0·97, 2·94
VDR: rs731236 (TaqI:G/A) 617 617
GG= 0 1 0·454 1 0·484
GA= 1 0·80 0·47, 1·35 0·92 0·53, 1·60
AA =2 0·78 0·45, 1·37 1·15 0·65, 2·04
VDR SNP: WHR: models 2·1–2·8
VDR: rs11568820 (CdX-2:T/C) 617 617
TT=0 1 0·363 1 0·891
CT= 1 0·80 0·27, 2·39 0·50 0·19, 1·32
CC= 2 1·06 0·37, 3·01 0·62 0·24, 1·56
VDR: rs1544410 (BsmI:G/A) 616 616
GG= 0 1 0·976 1 0·071†
GA= 1 0·92 0·59, 1·44 0·79 0·53, 1·16
AA =2 1·04 0·58, 1·87 0·63† 0·37, 1·06
VDR: rs7975232 (ApAI:A/C) 617 617
AA =0 1 0·821 1 0·024*
AC = 1 0·74 0·46, 1·17 1·53† 1·01, 2·34
CC= 2 0·98 0·57, 1·70 1·76* 1·06, 2·92
VDR: rs731236 (TaqI:G/A) 617 617
GG= 0 1 0·906 1 0·038*
GA= 1 0·90 0·51, 1·57 1·26 0·76, 2·09
AA =2 1·00 0·56, 1·78 1·69† 1·00, 2·87
Megalin SNP: WC: models 3·1–3·2 617 617
Megalin: rs3755166:G/A 0·387 0·665
GG= 0 1 1
GA= 1 1·06 0·64, 1·77 0·96 0·56, 1·63
AA =2 0·83 0·51, 1·32 1·09 0·69, 1·75
Megalin: rs2075252:C/T 617 0·577 617 0·920
CC= 0 1 1
CT= 1 0·69 0·43, 1·11 0·66† 0·42, 1·06
TT=2 1·08 0·57, 2·03 1·36 0·72, 2·56
Megalin: rs4668123:C/T 609 0·730 609
CC= 0 1 1 0·545
CT= 1 0·81 0·52, 1·25 0·91 0·60, 1·39
TT=2 1·74 0·82, 3·71 1·71 0·77, 3·77
Megalin SNP: WHR: models 4·1–4·2
Megalin: rs3755166:G/A 617 617
GG= 0 1 0·184 1 0·585
GA= 1 0·88 0·52, 1·47 1·00 0·62, 1·61
AA =2 0·72 0·45, 1·17 0·89 0·58, 1·37
Megalin: rs2075252:C/T 617 617
CC= 0 1 0·042* 1
CT= 1 1·08 0·68, 1·72 0·86 0·57, 1·30 0·367
TT=2 2·14* 1·15, 3·99 1·59 0·89, 2·81
Continued
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multiple testing, which was not the case of Megalin SNPHAP
(P>0·025).
Discussion
The present study examined longitudinal associations of VDR
and megalin gene polymorphisms with central adiposity, using
extensive data from the BLSA, an ongoing prospective open
cohort study. Study participants consisted of non-Hispanic
white adults residing in Baltimore city, with one or more visits
at age ≥50 years, and complete data (n 609–617). Available
repeated assessments on WC and WHR were used to form
four binary outcomes, which were deﬁned by multiple linear
mixed models, mid-follow-up age estimators for central adi-
posity level and annual rate of change with cut-points set at
Table 2. Continued
Predicted central adiposity outcomes‡
ECA SICA
n OR§ 95 % CI P for trend n OR§ 95 % CI P for trend
Megalin: rs4668123:C/T 609 609
CC= 0 1 0·093† 10 ·393
CT= 1 1·35 0·88, 2·08 0·95 0·65, 1·39
TT=2 1·69 0·75, 3·82 1·74 0·85, 3·55
ECA, elevated central adiposity; SICA, significant increase in central adiposity; WC, waist circumference; WHR, waist:hip ratio.
* P<0 ·05 for null hypothesis that Loge(OR)= 0.
† P<0 ·10 for null hypothesis that Loge(OR)=0.
‡ WC and WHR (ECA and SICA) were predicted using a linear mixed model controlling for sex, race/ethnicity, education (years), and smoking status, with age added among the
fixed-effect variables to allow for quadratic non-linear change (see online Supplementary Material S2 for more details).
§ Based on multiple logistic regression models with outcome being ECA or SICA for WC or WHR and main exposures being each VDR SNP (models 1·1–1·8o r2 ·1–2·8) or the
three megalin SNP (models 3·1–4·2). The model controlled for first-visit age, mean age at follow-up, sex, education, first-visit smoking status, first-visit self-reported type 2 dia-
betes, hypertension, CVD and the two principal component analysis factor scores.
Fig. 1. Associations of vitamin D receptor (VDR) and megalin SNP latent classes with elevated central adiposity (ECA) and significant increase in central adiposity
(SICA), for waist circumference (WC) (a) and waist:hip ratio (WHR) (b): multiple logistic regression model. VDR and megalin SNP latent classes were entered together
into the model as dummy variables. VDR1 and megalin1 SNP latent classes were taken as referent categories to which the other two SNP latent classes per gene were
contrasted. The model was adjusted for covariates listed in Tables 2 and 3. See Methods section for description of the four outcomes and the SNP latent classes. Values
are odds ratios, with 95 % CI represented by vertical bars. ** P<0 ·025 for null hypothesis that Loge(OR)=0. † P<0·10 for null hypothesis that Loge(OR)=0.
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and SICA-WC and SICA-WHR.
Selected SNP for VDR (four SNP: (1) rs11568820 (CdX-2:
T/C); (2) rs1544410 (BsmI:G/A); (3) rs7975232 (ApaI:A/C);
(4) rs731236 (TaqI:G/A)) and Megalin (three SNP: (1)
rs3755166:G/A; (2) rs2075252:C/T; (3) rs4668123:C/T)
were included as main exposures, from which SNPLC and
SNPHAP were created. Multiple logistic regression analyses
indicated that, in men, higher ECA-WHR odds were associ-
ated with SNPLC Megalin2:rs3755166[–]/rs2075252[TT]/
rs4668123[T–]( v. Megalin1:rs3755166[–]/rs2075252[CC]/
rs4668123[–]) (OR 2·87; 95 % CI 1·15, 7·12; P=0·023)
and that SNPLC Megalin3:rs3755166[–]/rs2075252[CT]/
rs4668123[–]( v. Megalin1) was linked to lower SICA-WC
odds (OR 0·48; 95 % CI 0·26, 0·88; P =0 ·019) (P >0 ·05
for sex× SNPLC). In women, VDR3 SNPHAP (GAA:bAT)
was related to lower odds of ECA-WC (OR 0·37; 95 % CI
0·16, 0·87; P =0·023) (P <0·05 for sex× SNPHAP), VDR1
SNPHAP (GCA:baT) was associated with greater odds and
VDR3 SNPHAP (GAA:bAT) with lower odds of SICA-WC
(P>0·05 for sex× SNPHAP).
Several recent cross-sectional and case–control studies have
examined VDR genetic polymorphisms as potential risk
markers for central adiposity and related metabolic dis-
orders
(9–11,16,17,36,37). When testing VDR SNP associations
with adiposity, a recent cross-sectional study (176 randomly
selected men aged 25–65 years) found that homozygous
BsmI (AA v. GG) was associated with higher BMI (29·0 v.
26·8 kg/m
2; P =0·024) and higher WC (101·8 v. 96·2 cm;
P =0·014)
(11). A similar ﬁnding was observed in another
cross-sectional study of 175 women with body weight and
fat mass as two outcomes and the VDR SNP BsmI being of
interest
(10). In a more recent study with a larger sample size
(n 1773) of women, the association of fourteen VDR SNP
with three adiposity measures was examined, including WC.
Results suggested that the homozygous rare variant of
rs3782905 found in the 3′ VDR region (LD between
rs3782905 and BsmI in Caucasian HapMap is about 0·42)
was associated on average with 4·4 cm larger WC compared
with the homozygous common variant (Bonferroni-adjusted
P=0·004)
(9). These consistent ﬁndings for BsmI and obesity
with the risk increasing allele being ‘A’ were conﬁrmed when
the phenotypes of interest were type 2 diabetes, fasting glucose
level and CHD risk in recent studies
(13,14). In contrast, among
351 postmenopausal healthy women, VDR BsmI polymorph-
ism (‘A’ risk allele) was not associated with obesity or insulin
resistance but was connected with an unfavourable lipid pro-
ﬁle
(36). Additionally, a case–control study with 309 unrelated
French subjects with type 2 diabetes, and among those with
early onset in particular, the TaqI SNP (‘A’ allele) was associ-
ated with a higher BMI and an increased prevalence of obesity,
compared with the controls
(16). The Cdx-2 SNP was related
only to BMI, fat mass and percentage fat mass in one study
of 1215 subjects from 400 Chinese nuclear families
(17).I n
Table 3. Vitamin D receptor (VDR) and Megalin gene SNP latent class (SNPLC) associations with predicted central adiposity outcomes, stratified by sex:
multiple logistic regression analysis (Baltimore Longitudinal Study of Aging)‡
(Odds ratios and 95 % confidence intervals)
Men Women
n OR§ 95 % CI Pn OR§ 95 % CI P
ECA
WC 368 245
VDR2 v. VDR1 1·32 0·67, 2·60 0·428 0·92 0·37, 2·27 0·854
VDR3 v. VDR1 1·24 0·70, 2·17 0·460 0·56 0·26, 1·19 0·132
Megalin2 v. Megalin1 1·59 0·65, 3·89 0·307 1·17 0·38, 3·59 0·788
Megalin3 v. Megalin1 0·60 0·32, 1·07 0·101 0·94 0·43, 2·07 0·882
WHR 367 253
VDR2 v. VDR1 0·84 0·40, 1·76 0·653 1·91 0·72, 5·10 0·197
VDR3 v. VDR1 0·85 0·48, 1·51 0·585 1·73 0·77, 3·89 0·180
Megalin2 v. Megalin1 2·87 1·15, 7·12 0·023** 2·44 0·76, 7·82 0·133
Megalin3 v. Megalin1 0·96 0·53, 1·75 0·906 1·48 0·65, 3·40 0·350
SICA
WC 368 245
VDR2 v. VDR1 1·36 0·67, 2·77 0·395 0·68 0·26, 1·79 0·438
VDR3 v. VDR1 1·28 0·72, 2·27 0·398 1·12 0·55, 2·28 0·747
Megalin2 v. Megalin1 1·22 0·45, 3·32 0·699 1·17 0·40, 3·46 0·771
Megalin3 v. Megalin1 0·48 0·26, 0·88 0·019** 1·18 0·55, 2·53 0·673
WHR 368 243
VDR2 v. VDR1 0·53 0·26, 1·05 0·069† 1·18 0·49, 2·83 0·711
VDR3 v. VDR1 1·05 0·63, 1·76 0·842 2·08 1·03, 4·17 0·040*
Megalin2 v. Megalin1 1·55 0·64, 3·78 0·333 1·67 0·57, 4·90 0·351
Megalin3 v. Megalin1 0·67 0·39, 1·16 0·153 1·47 0·71, 3·03 0·300
ECA, elevated central adiposity; WC, waist circumference; WHR, waist:hip ratio; SICA, significant increase in central adiposity.
Significance for null hypothesis that Loge(OR)=0: * P<0·05, ** P<0·025.
† P<0 ·10 for null hypothesis that Loge(OR)=0.
‡ WC and WHR (ECA and SICA) were predicted using a linear mixed model controlling for sex, race/ethnicity, education (years), and smoking status, with age added among the
fixed-effect variables to allow for quadratic non-linear change (see online Supplementary Material S2 for more details).
§ Based on multiple logistic regression models with outcome being ECA or SICA for WC or WHR and main exposures being VDR and megalin SNPLC entered simultaneously into
the model for each outcome, stratifying by sex. The model controlled for first-visit age, mean age at follow-up, education, first-visit smoking status, first-visit self-reported type 2
diabetes, hypertension, CVD and the two principal component analysis factor scores.
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appeared to signiﬁcantly increase the odds of SICA-WHR
(P for trend= 0·024).
Few previous studies have examined VDR SNPHAP (in
addition to SNP) as predictors of adiposity, and none found
signiﬁcant associations (for example, Gu et al.
(17)). However,
other studies examined VDR SNPHAP in relation to diabetes
(types 1 and 2), insulin resistance and cardiovascular out-
comes. For instance, in a population-based study of men
and women aged 55–80 years, each copy of the baT haplotype
was associated with a 20 % increased likelihood of
electrocardiogram-conﬁrmed myocardial infarction, after
adjustment for established CVD risk factors
(38). The latter
ﬁnding suggests that baT, which we found to increase the
risk of longitudinal increase in WC among women, may also
be a risk factor for cardiovascular events.
Although no prior research had tested the association
between VDR SNPLC and megalin (SNP, SNPHAP or
SNPLC) and adiposity, we found that they might be important
risk factors for central adiposity (ECA and SICA), in some
cases only in one sex. Thus, our ﬁndings need to be replicated
in larger samples of adult men and women with repeated
measures on WC and WHR before efforts to uncover poten-
tial reasons for sex differences can be made.
Although the exact mechanism is unknown, evidence sup-
ports the role of vitamin D on adiposity. In vitro studies
have shown that vitamin D stabilises VDR and suppresses
adipocyte differentiation through C/EBPα (cytidine-cytidine-
adenosine-adenosine-thymidine (CCAAT)/enhancer binding
protein α) inhibition and PPARγ expression and activity
(39).
VDR overexpression inhibited adipocyte differentiation inde-
pendently of vitamin D, suggesting that the VDR plays a cru-
cial role in adipocyte maturation. If the polymorphisms in
VDR and megalin are functional or are tagging SNP that
alter the availability or activity of vitamin D, it is conceivable
that these SNP inﬂuence adiposity traits through the regulation
of adipocyte differentiation. The Cdx-2 polymorphism in
VDR has been shown to have an effect on VDR activity
while the TaqI-ApaI-BsmI SNP in the 3′ untranslated region
of the gene is thought to be a tag SNP
(40). In the present
study, the 3′ region SNP were more strongly associated with
longitudinal adiposity trajectory; therefore ﬁne mapping of
this region to identify the functional SNP may provide insight
into the mechanism by which VDR SNP regulate adiposity
traits. The two non-synonymous SNP in megalin
(rs2075252, rs3668123) were driving the association between
megalin and adiposity traits
(41). Whether these coding SNP
inﬂuence megalin gene function is unknown. However, if
Fig. 2. Associations of vitamin D receptor (VDR) and megalin SNP haplotypes with elevated central adiposity (ECA) and significant increase in central adiposity
(SICA), for waist circumference (WC) (a) and waist:hip ratio (WHR) (b): multiple logistic regression model. VDR and megalin SNP haplotypes were entered separately
into the model as an ordinal variable (0, 1, 2). The model was adjusted for covariates listed in Tables 2 and 3. See Methods section for description of the four out-
comes and the SNP haplotypes. Values are odds ratios, with 95 % CI represented by vertical bars. * P <0 ·05 for null hypothesis that Loge(OR)= 0. † P<0 ·10 for null
hypothesis that Loge(OR) = 0.
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and thereby regulate adipocyte differentiation.
The present study has several strengths. It included a large
number of consecutive visits per participant, and made use
of advanced statistical techniques by combining linear mixed
models with multiple logistic regression analyses
(42) to examine
associations between gene SNP, SNPLC (deﬁned using LCA)
and SNPHAP (deﬁned using haplotype analysis) and four
measures of central adiposity status and change.
However, in light of some limitations, ﬁndings of the pre-
sent study must be interpreted with caution. Indeed, the
BLSA is an open cohort study of a convenience sample of par-
ticipants, experiencing continuous recruitment and dropout.
Moreover, genetic data were available only for a subset of
the initial cohort, yielding a smaller sample size and a younger
mean age. To reduce selection biases resulting from this
sampling scheme, we used a number of statistical techniques,
including a two-stage Heckman selection model. Further, even
though observation frequency for central adiposity was high
(mean about ﬁve visits), the data structure was largely unba-
lanced given that ﬁrst-visit age and duration between visits var-
ied across participants. Consequently, we used mixed models
to predict the continuous version of the four adiposity out-
comes at mean follow-up age. Our main statistical models
also controlled for mean follow-up and ﬁrst-visit age.
Moreover, no data were readily available on potential confoun-
ders including serum vitamin D, dietary intakes of Ca and vita-
min D; physical activity particularly outdoors exercise which is
a main determinant of vitamin D status and is also one of the
main protective lifestyle factors related to obesity; alcohol or
drug use and use of medications. Finally, we cannot rule out
chance, residual confounding or selection bias for positive
ﬁndings, particularly for the sex-speciﬁc analyses, and lack of
power for negative ﬁndings. Thus, until those ﬁndings are
further replicated in another independent sample, they should
be interpreted with caution.
In conclusion, the key ﬁndings of the present study point to
a relationship between VDR and megalin gene polymorphisms
Table 4. Vitamin D receptor (VDR) and Megalin gene SNP haplotype (SNPHAP) associations with predicted central adiposity outcomes, stratified by sex:
multiple logistic regression analysis (Baltimore Longitudinal Study of Aging)§
(Odds ratios and 95 % confidence intervals)
Men Women
n OR‖ 95 % CI Pn OR‖ 95 % CI P
ECA
WC 364 236
VDR1, GCA (0, 1, 2) 0·89 0·62, 1·28 0·534 1·15 0·71, 1·87 0·562
VDR2, AAG (0, 1, 2) 1·04 0·73, 1·50 0·817 1·30 0·82, 2·06 0·256
VDR3, GAA (0, 1, 2) 1·25 0·73, 2·13 0·417 0·37 0·16, 0·87 0·023**‡
Megalin1, GCC (0, 1, 2) 1·00 0·69, 1·44 0·995 1·41 0·89, 2·23 0·145
Megalin2, ACC (0, 1, 2) 1·13 0·77, 1·66 0·538 0·62 0·36, 1·05 0·076†
Megalin3, GTT (0, 1, 2) 0·95 0·54, 1·68 0·862 0·97 0·49, 1·93 0·927
WHR 363 236
VDR1, GCA (0, 1, 2) 1·01 0·70, 1·46 0·959 0·96 0·56, 1·61 0·894
VDR2, AAG (0, 1, 2) 1·06 0·73, 1·53 0·759 0·90 0·55, 1·48 0·692
VDR3, GAA (0, 1, 2) 0·92 0·52, 1·63 0·764 1·38 0·66, 2·88 0·393
Megalin1, GCC (0, 1, 2) 1·07 0·74, 1·55 0·730 0·84 0·51, 1·37 0·485
Megalin2, ACC (0, 1, 2) 0·92 0·61, 1·37 0·674 0·55 0·30, 1·00 0·049*
Megalin3, GTT (0, 1, 2) 1·66 0·95, 2·88 0·075† 1·41 0·70, 2·82 0·332
SICA
WC 364 242
VDR1, GCA (0, 1, 2) 1·08 0·74, 1·56 0·692 1·87 1·14, 3·07 0·014**
VDR2, AAG (0, 1, 2) 1·02 0·71, 1·49 0·895 0·88 0·56, 1·37 0·568
VDR3, GAA (0, 1, 2) 0·84 0·49, 1·45 0·535 0·40 0·19, 0·87 0·020**
Megalin1, GCC (0, 1, 2) 0·89 0·61, 1·30 0·552 1·08 0·68, 1·71 0·746
Megalin2, ACC (0, 1, 2) 1·29 0·87, 1·91 0·212 0·76 0·46, 1·25 0·278
Megalin3, GTT (0, 1, 2) 0·72 0·40, 1·31 0·286 1·00 0·52, 1·90 0·990
WHR 364 234
VDR1, GCA (0, 1, 2) 1·34 0·96, 1·88 0·090† 1·52 0·97, 2·38 0·065†
VDR2, AAG (0, 1, 2) 0·77 0·55, 1·09 0·138 0·74 0·48, 1·13 0·165
VDR3, GAA (0, 1, 2) 0·97 0·59, 1·60 0·903 0·89 0·47, 1·72 0·739
Megalin1, GCC (0, 1, 2) 1·05 0·75, 1·48 0·760 0·85 0·55, 1·32 0·475
Megalin2, ACC (0, 1, 2) 0·86 0·60, 1·24 0·414 0·82 0·51, 1·31 0·406
Megalin3, GTT (0, 1, 2) 0·83 0·49, 1·43 0·510 1·43 0·79, 2·60 0·237
ECA, elevated central adiposity; WC, waist circumference; WHR, waist:hip ratio; SICA, significant increase in central adiposity.
Significance for null hypothesis that Loge(OR)=0: *P<0·05, **P<0 ·025.
† P<0 ·10 for null hypothesis that Loge(OR)=0.
‡P<0·05 for null hypothesis that sex×SNPHAP interaction term= 0 in a model where main effect of sex was added.
§WC and WHR were predicted at mean age at follow-up using a multivariate linear mixed model controlling for sex, race/ethnicity, education (years), and smoking status, with age
added among the fixed-effect variables to allow for quadratic non-linear change. The slope or annual rate of change was predicted from these models at the mean age at follow-up
(i.e. between age 50 years and individual mean age of follow-up for each central adiposity measure) (see online Supplementary Material S2 for more details).
║ Based on multiple logistic regression models with outcome being ECA or SICA for WC or WHR and main exposures being VDR and megalin SNPHAP entered simultaneously
into the model for each outcome, stratifying by sex. The model controlled for first-visit age, mean age at follow-up, education, first-visit smoking status, first-visit self-reported type 2
diabetes, hypertension, CVD and the two principal component analysis factor scores.
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journals.cambridge.org/jnsand central adiposity. To our knowledge this is the ﬁrst study
to examine longitudinal change in central adiposity in relation
to polymorphisms in those two genes. However, further
research is needed to replicate those ﬁndings in different
populations, including populations of other racial and ethnic
groups, in order to conﬁrm the biological signiﬁcance of
those polymorphisms in relation to central adiposity
phenotypes.
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